Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Knight-Swift Transportation Holdings Inc. (KNX) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

Knight-Swift Transportation Holdings Inc.Trade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Knight-Swift Transportation Holdings Inc. vs Vaxcyte Inc. Common Stock — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $63.5 (market cap $10.26B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Knight-Swift Transportation Holdings Inc. and Vaxcyte Inc. Common Stock are close in size by market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.27% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

KNXPCVX
Market Cap
$10.26B$10.51B
Volume
4,530,0772,644,694
Sector
IndustrialsHealth
52-Week High
$82.45$73.82
52-Week Low
$41.68$40.32
Typical Hold Time
6 Days0 Days
Enterprise Value
$12.75B$9.14B
Dividend Yield
1.27%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Knight-Swift Transportation Holdings Inc.

Knight-Swift Transportation (KNX) trades at $63.01, down 2.34% with bearish technical signals. The company reported mixed earnings with Q2 2026 beating estimates but Q4 2025 missing expectations. Revenue trends show modest growth to $7.7B in 2026, though net income margin compression to 0.55% raises concerns. Analyst consensus remains strongly bullish with 64% buy ratings and $85.75 price target, while technical indicators show selling pressure with support at $63.

The stock presents a divergence between strong Wall Street optimism and current technical weakness. Upside potential exists from truckload margin improvements and capacity-driven freight recovery, but risks include margin pressure, CEO stock sales, and broader transportation sector volatility. The upcoming Q3 2026 earnings report on October 21, 2026 will be critical for validating the bullish analyst thesis.

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KNX

No sentiment data available yet.

PCVX
100% Buy0% Sell
Avg holding period · 0 Days

About Knight-Swift Transportation Holdings Inc.

Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.

Read more on KNX →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →